Related Experiment Videos
Cohort profile: King's Health Partners bladder cancer biobank
Pinky Kotecha1, Charlotte L Moss2, Deborah Enting3
1Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Hospital, 3rd Floor Bermondsey Wing, London, SE1 9RT, UK.
Insights
The King's Health Partners Biobank collected bladder cancer (BC) patient samples and data, creating a representative resource for future research. This initiative aims to advance understanding and improve outcomes for this common cancer.
Area of Science:
- Oncology
- Urology
- Biobanking
Background:
- Bladder cancer (BC) is a prevalent global malignancy with limited progress in patient outcome improvement over 25 years.
- The King's Health Partners (KHP) BC Biobank was established to address critical, clinically relevant BC research questions.
- Patient recruitment occurs within Urology and Oncology departments, with consent obtained throughout the treatment pathway.
Purpose of the Study:
- To establish a comprehensive biobank for bladder cancer research.
- To collect and preserve patient samples (blood, urine, tissue) and associated clinical data.
- To create a demographically and clinically representative resource for the South East London BC population.
Main Methods:
- Recruitment of bladder cancer patients from Guy's Hospital between June 2017 and June 2019.
- Obtained consent from 53.3% (531/997) of BC patients for sample and data donation.
- Collected fresh frozen tumor samples, fixed paraffin-embedded samples, blood, and urine, processing them into derivatives.
Main Results:
- Collected 193 peripheral blood mononuclear cell vials, 238 plasma vials, 224 serum vials, 414 urine supernatant vials, and 104 urine cell pellets.
- Acquired fresh frozen tumor samples from 90/178 surgical procedures and paraffin-embedded samples from all consenting patients.
- The biobank population is demographically and clinically representative of the KHP catchment area.
Conclusions:
- The KHP BC Biobank has successfully created a rich repository of data and tissue.
- This biobank serves as a valuable resource for advancing bladder cancer research.
- The collected materials are representative of the local South East London bladder cancer patient population.
Background:
Bladder cancer (BC) is the 9th most common cancer worldwide, but little progress has been made in improving patient outcomes over the last 25 years. The King's Health Partners (KHP) BC biobank was established to study unanswered, clinically relevant BC research questions. Donors are recruited from the Urology or Oncology departments of Guy's Hospital (UK) and can be approached for consent at any point during their treatment pathway. At present, patients with bladder cancer are approached to provide their consent to provide blood, urine and bladder tissue. They also give access to medical records and linkage of relevant clinical and pathological data across the course of their disease. Between June 2017 and June 2019, 531 out of 997 BC patients (53.3%) gave consent to donate samples and data to the Biobank. During this period, the Biobank collected fresh frozen tumour samples from 90/178 surgical procedures (of which 73 were biopsies) and had access to fixed, paraffin embedded samples from all patients who gave consent. Blood and urine samples have been collected from 38 patients, all of which were processed into component derivatives within 1 to 2 h of collection. This equates to 193 peripheral blood mononuclear cell vials; 238 plasma vials, 224 serum vials, 414 urine supernatant vials and 104 urine cell pellets. This biobank population is demographically and clinically representative of the KHP catchment area.
Conclusion:
The King's Health Partners BC Biobank has assembled a rich data and tissue repository which is clinically and demographically representative of the local South East London BC population, making it a valuable resource for future BC research.